



iTrack™ Canaloplasty to be Featured at the 38th International Congress of the German Ophthalmic Surgeons (DOC) in Nuremberg

Adelaide, Australia, 3 June, 2026 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology platform will be featured in three podium presentations during the official scientific program of the 38th International Congress of the German Ophthalmic Surgeons (DOC), taking place at the NCC Ost in Nuremberg, Germany, 18-20 June 2026.

This year's DOC Congress will offer in-depth insights into canaloplasty covering long-term clinical outcomes, real-world performance and its versatility across the spectrum of glaucoma severity – including 10-year follow-up data and the latest results from the iTrack Global Data Registry.

A summary of the DOC 2026 podium presentations featuring the iTrack™ canaloplasty technology platform is included below:

Podium Presentations

FP 1 – Free Paper: Glaucoma
Friday, 19 June 2026
10:30-11:42

“10-Year Efficacy and Safety of iTrack Ab-Interno Canaloplasty in Primary Open-Angle Glaucoma”

Norbert Koerber, MD; Simon Ondrejka, MD

“Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma”

Karsten Klabe, MD; Keith Barton, MD; Karl Mercieca, MD

“3-Year Outcomes of Ab-Interno Canaloplasty With iTrack Advance in Moderate Open-Angle Glaucoma”

Simon Ondrejka, MD; Norbert Koerber, MD



Full session details can be accessed via the DOC Congress program.

All educational content of the DOC Congress is planned by its Scientific Committee. The DOC does not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use (USA): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not an on-label indication in the USA.*

** The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.*

Indications for Use (International): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.



For additional information about the *iTrack™ Advance*, including safety information, please visit: <https://itrack-advance.com>

For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu